Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Related AZN
US Stock Futures Signal Lower Start On Wall Street
AstraZeneca to Sell Caprelsa to Sanofi's Genzyme for Up to $300M
Gilead's Next Big Acquisition: Where Will They Expand? (Seeking Alpha)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

Jul 2015BerenbergUpgradesHoldBuy
May 2015LBBWUpgradesSellHold
Feb 2015SEB Equity ResearchUpgradesHoldBuy

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings


Related Articles (AZN)

Get Benzinga's Newsletters